Gainers

• iSpecimen (NASDAQ:ISPC) shares rose 20.2% to $0.41 during Friday's pre-market session. The market value of their outstanding shares is at $3.3 million.
• WORK Medical Tech Gr (NASDAQ:WOK) shares moved upwards by 16.79% to $1.46.
• Encompass Health (NYSE:EHC) shares rose 14.5% to $114.0. The market value of their outstanding shares is at $10.0 billion. The company's, Q4 earnings came out yesterday.
• Envista Holdings (NYSE:NVST) stock rose 14.12% to $28.2. The company's market cap stands at $4.0 billion. As per the press release, Q4 earnings came out yesterday.
• PepGen (NASDAQ:PEPG) shares moved upwards by 11.88% to $4.8. The market value of their outstanding shares is at $294.9 million.
• BNB Plus (NASDAQ:BNBX) stock increased by 11.47% to $0.96. The market value of their outstanding shares is at $3.7 million.

Losers

• Doximity (NYSE:DOCS) stock fell 30.6% to $23.11 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 billion. As per the press release, Q3 earnings came out yesterday.
• Molina Healthcare (NYSE:MOH) shares decreased by 27.62% to $128.0. The market value of their outstanding shares is at $9.0 billion. As per the press release, Q4 earnings came out yesterday.
• Ernexa Therapeutics (NASDAQ:ERNA) stock declined by 26.68% to $0.5. The company's market cap stands at $5.3 million.
• Biodexa Pharmaceuticals (NASDAQ:BDRX) stock fell 10.01% to $1.17. The market value of their outstanding shares is at $1.0 million.
• Mustang Bio (NASDAQ:MBIO) shares fell 9.37% to $0.65. The company's market cap stands at $5.1 million.
• Venus Concept (NASDAQ:VERO) shares decreased by 9.33% to $1.07. The market value of their outstanding shares is at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.